B. Kodal

发表

Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager

Jeffrey S. Miller, M. Geller, D. Vallera, 2020, Cancer Immunology Research.

Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.

Paul C. Rogers, Cheng-Ying Wu, Bin Zhang, 2021, Cell stem cell.

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity

M. Geller, Y. Soignier, T. Lenvik, 2022, Journal for ImmunoTherapy of Cancer.

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Jeffrey S. Miller, D. Weisdorf, V. Bachanova, 2019, Blood advances.

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo

S. Ferrone, Jeffrey S. Miller, C. Ryan, 2020, Cancers.

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer

M. Geller, D. Vallera, M. Felices, 2021, Cancers.

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

I. Pastan, R. Kratzke, D. Vallera, 2023, Frontiers in Immunology.

470 Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors

Jeffrey S. Miller, D. Vallera, Bahram Valamehr, 2020 .

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

A. Skubitz, H. Wong, J. Miller, 2017, Gynecologic oncology.

Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

A. Skubitz, Jeffrey S. Miller, L. Uppendahl, 2019, Gynecologic oncology.

Early assessment of dosimetric and biological differences of total marrow irradiation versus total body irradiation in rodents.

G. Storme, P. Alaei, Daohong Zhou, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.

Bahram Valamehr, Z. Davis, A. Witty, 2022, Blood.

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA

D. Vallera, M. Felices, B. Kodal, 2023, Immuno.

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia

Jeffrey S. Miller, J. Gotlib, D. Weisdorf, 2017, American journal of hematology.

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Jeffrey S. Miller, D. Weisdorf, M. Geller, 2017 .